Scholars@Duke
Annick Desjardins

Annick Desjardins

Professor of Neurosurgery
Neurosurgery, Neuro-Oncology
annick.desjardins@duke.edu
Duke Box 3624, Durham, NC 27710
the Preston Robert Tisch Brain, Rm. 047 Baker House, DUMC 3624, Durham, NC 27710

Scholarly Works - Conferences

Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm.

Conference Journal of Clinical Oncology · June 1, 2024 2079Background: Bizaxofusp (MDNA55) is designed to selectively deliver a potent toxin payload to tumor cells by targeting the IL-4 receptor (IL-4R) overexpressed by GBM, but not normal brain. Localized delivery of bizaxofusp minimizes risk of off-target to ... Full text Cite

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma

Conference Journal of Clinical Oncology · January 1, 2024 Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety a ... Full text Cite

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.

Conference Invest New Drugs · December 2020 Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in recu ... Full text Link to item Cite

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Conference Support Care Cancer · October 2016 BACKGROUND: In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially comp ... Full text Link to item Cite

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

Conference Neuro Oncol · June 2016 BACKGROUND: The proteasome plays a vital role in the physiology of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM. Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structur ... Full text Link to item Cite